MENU
Showcases Stock ranks Forex

Precision Biosciences Inc (DTIL)
1.61  -0.13 (-7.47%) 08-08 16:00
Open: 1.77 Pre. Close: 1.74
High: 1.76 Low: 1.55
Volume: 1,936,384 Market Cap: 178M
Precision BioSciences, Inc., a clinical stage gene editing company, develops vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which a specific type of immune cell, called a T cell, is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.771 - 1.78 1.78 - 1.786
Low: 1.531 - 1.541 1.541 - 1.548
Close: 1.594 - 1.611 1.611 - 1.621
Stock Technical Analysis
Overall:     
Target: Six months: 2.07
One year: 2.41
Support: Support1: 1.55
Support2: 1.41
Resistance: Resistance1: 1.77
Resistance2: 2.07
Pivot: 1.59
Moving Averages: MA(5): 1.64
MA(20): 1.56
MA(100): 1.95
MA(250): 5.74
MACD: MACD(12,26): 0.02
Signal(12,26,9):
%K %D: %K(14,3): 74.86
%D(3): 71.90
RSI: RSI(14): 51.36
52-Week: High: 14.38
Low: 1.11
Change(%): -83.1
Average Vol(K): 3-Month: 3300
10-Days: 1525
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.

[ DTIL ] has closed below upper band by 44.7%. Bollinger Bands are 51% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 22 bars. This is a sign that the market may be about to initiate a new trend.
Stock chart
Stock News
Mon, 08 Aug 2022
Precision Biosciences Inc Down 8.83% To $1.59 After Earnings Miss - InvestorsObserver

Fri, 05 Aug 2022
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues - Nasdaq

Thu, 04 Aug 2022
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2 - Nasdaq

Wed, 03 Aug 2022
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark - Nasdaq

Mon, 25 Jul 2022
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GuruFocus.com

Mon, 25 Jul 2022
Precision BioSciences, Inc. (NASDAQ:DTIL) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 110.79
Shares Float (M) 44.28
% Held by Insiders 19.28
% Held by Institutions 38.49
Shares Short (K) 1940
Shares Short Prior Month (K) 2810
Stock Financials
EPS -0.670
Book Value (p.s.) 1.130
Profit Margin -39.10
Operating Margin -46.84
Return on Assets (ttm) -13.5
Return on Equity (ttm) -62.4
Qtrly Rev. Growth -79.7
Gross Profit (p.s.) 1.043
Sales Per Share 0.925
EBITDA (p.s.) -0.354
Qtrly Earnings Growth
Operating Cash Flow (M) -107.80
Levered Free Cash Flow (M) -35.07
Stock Valuation
PE Ratio -2.40
PEG Ratio
Price to Book value 1.42
Price to Sales 1.74
Price to Cash Flow -1.65
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android